h.c. wainwright news - Search News

Syros cut to neutral by H.C. Wainwright on failed drug study

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a Phase 3 study of the company’s drug tamibarotene had failed to meet its primary endpoint.

YAHOO!Finance · 1d

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed,

MarketWatch · 2d

Syros Pharmaceuticals Shares Plummet Premarket After Study Failure

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer. Syros late Tuesday said the Phase 3 study evaluating tamibarotene in combination with azacitidine in newly diagnosed patients with higher-risk myelodysplastic syndrome didn't meet its primary endpoint of complete response rate,

electroCore price target raised to $22 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on electroCore (ECOR) to $22 from $15 and keeps a Buy rating on the shares after the firm ...

3don MSN

Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...

bovnews18m

OPKO Health Inc (OPK) Stock: More Resilient Than It Appears

On Thursday, OPKO Health Inc (OPK) stock saw a modest uptick, ending the day at $1.62 which represents a slight increase of $0.02 or 1.25% from the prior close of $1.6. The stock opened at $1.58 and ...

17h

Adaptimmune price target lowered to $3.50 from $4 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the ...

Yahoo Finance1d

Opus Genetics reinstated with a Buy at H.C. Wainwright

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes ...

WidePoint Corporation (AMEX:WYY) Q3 2024 Earnings Call Transcript

WidePoint Corporation (AMEX: WYY) Q3 2024 Earnings Call Transcript November 13, 2024 ...

bovnews1h

The SpringWorks Therapeutics Inc Enigma: What’s Causing the Wild Swings in SWTX Stock?

On Thursday, SpringWorks Therapeutics Inc (SWTX) stock saw a modest uptick, ending the day at $36.55 which represents a slight increase of $1.84 or 5.30% from the prior close of $34.71. The stock ...

MARA Holdings Faces Mixed Analyst Sentiment: Revenue Miss And Conservative Forecasts Amid Bitcoin Rally

MARA shares down as Q3 earnings miss estimates with lower revenue and adjusted loss, analysts maintain mixed views and price ...

The Bakersfield Californian1d

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Nasdaq23d

Ocuphire Pharma rating placed under review at H.C. Wainwright

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. The views and opinions expressed herein are the ...

H.C. Wainwright Reaffirms Their Hold Rating on Bolt Biotherapeutics (BOLT)

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report).

Some results have been hidden because they may be inaccessible to you

Show inaccessible results